MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
9.5200
-0.3700 (-3.74%)
NASDAQ · Last Trade: Oct 16th, 1:37 PM EDT
Detailed Quote
Previous Close
9.890
Open
9.820
Bid
9.530
Ask
9.550
Day's Range
9.320 - 10.13
52 Week Range
5.950 - 62.75
Volume
2,959,473
Market Cap
-
PE Ratio (TTM)
-3.424
EPS (TTM)
-2.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
10,152,757
Chart
About MoonLake Immunotherapeutics - Class A Ordinary Shares (MLTX)
MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing novel therapeutics for the treatment of autoimmune and inflammatory diseases. Leveraging its advanced proprietary platform, the company works on innovative approaches to enhance patient outcomes and address unmet medical needs in this therapeutic area. By integrating cutting-edge research and development strategies, MoonLake aims to bring new treatment options to market that can significantly improve the quality of life for individuals affected by chronic diseases. Their commitment to science and patient care drives their mission to transform the landscape of immunotherapy. Read More
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers and acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”). MoonLake is a clinical-stage biotechnology company.
The DJS Law Group reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options
The DJS Law Group announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of the securities laws.
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of MoonLake Immunotherapeutics (“MoonLake” or “the Company”) (NASDAQ: MLTX) for violations of the securities laws.
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In MoonLake To Contact Him Directly To Discuss Their Options
U.S. markets kicked off the week quietly, but certain stocks were anything but dull. Cannabis names surged after a Trump-endorsed CBD video went viral, while biotech firm MoonLake was crushed by disastrous trial results. Meanwhile, macro tension builds with a potential U.S. government shutdown and Friday’s key jobs report looming.
